Skip to content

Platelet-rich Fibrin(PRF) Membrane in Ophthalmic Diseases

Application of Platelet-rich Fibrin(PRF) Membrane in Ophthalmic Diseases

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06200727
Enrollment
170
Registered
2024-01-11
Start date
2023-01-01
Completion date
2025-12-31
Last updated
2024-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma, Macular Holes, Platelet-rich Fibrin, Pterygium

Keywords

PRF; pterygium; macular hole; corneal ulcer

Brief summary

The goal of this clinical trial is to observe the role of PRF in treating ophthalmic diseases.The efficacy and safety of PRF were validated for four ophthalmic conditions: macular hole, pterygium, corneal ulcer, and patients undergoing trabeculectomy for glaucoma. The main question aims to answer is PRF's effectiveness in ocular surface and fundus diseases. Participants will be divided into 2 groups, the experimental group will be treated with PRF and the control group will be treated with conventional surgery, with a 12-month postoperative follow-up to determine the role of PRF on wound healing in ophthalmic diseases.

Detailed description

Patients suffering from pterygium, macular hole, corneal ulcer, and glaucoma requiring for trabeculectomy , who visited Renmin Hospital of Whuhan University, were chosen to participate in this study. The participants were randomly divided into the experimental group (PRF group) and the control group (conventional group). The PRF group received PRF membrane treatment, while the conventional group received conventional surgical treatment. Before and after surgery, participants underwent a comprehensive ophthalmological exam at 1 week, 1 month, 3 months, 6 months, and 12 months. The outcome indicators are monitored and can vary depending on the disease. Participants with pterygium were examined for graft dissolution and complications. Participants with macular hole were monitored for hole closure, visual acuity recovery, and retinal blood flow recovery. Participants with corneal ulcer were monitored for lesion healing and complications such as degree of corneal vascularization and opacity. Participants with glaucoma were monitored for postoperative intraocular pressure (IOP), degree of conjunctival leakage in the filtration zone, and degree of scarring in the filtration zone.

Interventions

PROCEDUREPRF membrane tamponade surgery in macular hole

A specially formulated PRF membrane, as described previously, was filled into the macular hole to promote fissure repair.

PROCEDUREILM peeling in macular hole

The treatment of the macular hole was ILM peeling.

PROCEDUREPRF membrane grafting in pterygium

Used of autologous PRF membrane to cover the exposed conjunctiva after pterygium excision.

PROCEDUREAutologous conjunctival transplantation in pterygium

Used of autologous conjunctiva to cover exposed sclera after pterygium excision

PROCEDUREautologous PRF membrane grafting in trabeculectomy for glaucoma

Used of autologous PRF membranes to cover the exposed sclera after trabeculectomy for glaucoma.

PROCEDUREAmniotic membrane in trabeculectomy for glaucoma

Used of amniotic to cover the exposed sclera after trabeculectomy for glaucoma.

PROCEDUREPRF membrane grafting incorneal ulcer

After surgical debridement of corneal ulcers, autologous PRF membrane was placed over the corneal wound to promote corneal healing

PROCEDUREAmniotic membrane in corneal ulcer

After surgical debridement of corneal ulcers, autologous amniotic membrane was placed over the corneal wound to promote corneal healing

Sponsors

Lei Du
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

1. Diagnosis of macular hole confirmed by fundus examination; 2. Diagnosis of pterygium by slit lamp; 3. Patients requiring trabeculectomy for glaucoma; 4. Diagnosis of corneal ulcer confirmed by slit lamp.

Exclusion criteria

1. Combination of other active ophthalmic diseases, such as acute conjunctivitis and uveitis; 2. Previous history of ophthalmic trauma and ophthalmic surgery; 3. Recent use of anticoagulant or antiplatelet drugs; 4. Combination of serious systemic diseases such as hypertension and diabetes mellitus.

Design outcomes

Primary

MeasureTime frameDescription
Whether the corneal ulcer is healing in participants with corneal ulcer(Unit: yes/no)Pre-operation, and at 1 week, 1 month, 3 months, and 6 months post-operation.The investigators use a slit lamp to examine the anterior segment of the eye to assess the corneal wound healing rate. The PRF membrane-covered group is compared to the control group.
Whether the macular hole is closed in participants with macular hole(Unit: yes/no)Pre-operation, and at 1 week, 1 month, 3 months, and 6 months post-operation.Using optical coherence tomography(OCT )to see if the macular hole is healing to compare the healing rate between the PRF membrane filling group and the ILM peeling group.
Whether the wound heals completely after pterygium excision in participants with pterygium(Unit: yes/no)Pre-operation, and at 1 week, 1 month, 3 months, and 6 months post-operation.Observation of the anterior segment of the eye using a slit lamp to determine whether the wound is healed after pterygium excision and to compare the healing rate between the PRF membrane-covered group and the autologous conjunctival-covered group.
IOP in participants undergoing trabeculectomy for glaucoma(Unit: mmHg)Pre-operation, and at 1 week, 1 month, 3 months, and 6 months post-operation.Measurement of IOP using an IOP meter to compare the effect of IOP reduction in glaucoma treatment in the PRF membrane group and the amniotic membrane group.

Secondary

MeasureTime frameDescription
Best-corrected visual acuity (BCVA) in participants with macular hole(Unit: logMAR)Pre-operation, and at 1 week, 1 month, 3 months, and 6 months post-operation.Measurement of BCVA in participants with macular holes using an international standard logarithmic visual acuity chart.
Occurrence of complications in participants with pterygium(Unit: rate)Pre-operation, and at 1 week, 1 month, 3 months, and 6 months post-operation.Using a slit lamp, visualizing the anterior eye segment to detect complications in participants with pterygium.
Degree of tissue scarification in participants undergoing trabeculectomy for glaucoma(Unit: mild, moderate, severe)Pre-operation, and at 1 week, 1 month, 3 months, and 6 months post-operation.Viewing the anterior segment of the eye using a slit lamp to determine the extent of tissue scarring in participants undergoing trabeculectomy for glaucoma.
Occurrence of complications in participants with corneal ulcer(Unit: rate)Pre-operation, and at 1 week, 1 month, 3 months, and 6 months post-operation.Using a slit lamp, visualizing the anterior eye segment to detect complications in participants with corneal ulcer.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026